← Oncology Approval Tracker

FDA DECISION ·

Tecentriq

atezolizumab · Genentech

FDA approvalNew dosing regimenMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 840 mg every two weeks and 1,680 mg every four weeks as alternatives to 1,200 mg every three weeks for six then-labeled combination uses across hepatocellular carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer, BRAF V600-mutated melanoma and PD-L1-positive advanced triple-negative breast cancer. FDA later withdrew the listed breast cancer use.

LAMPGEN ANALYSIS

Why it matters

FDA used pharmacokinetic modeling and safety evidence to support alternative infusion intervals in the named combination settings.

What research teams should watch

Retain regimen-specific dose and interval and check the label version before counting the historical breast cancer use.

PRIMARY RECORDS

Sources